Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Brain Cancer
Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cancer Topics, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Endocrine Cancer, Gastrointestinal Cancers, General Oncology, Gynecologic Cancer, Head and Neck Cancer, Hematologic Cancers, Lung Cancer, Lymphoma, Multiple Myeloma, Pancreatic Cancer, Pediatric Cancer, Prostate Cancer, Renal Cell Carcinoma, Sarcoma, Skin Cancer, Urologic Cancers
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%…
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
Immunotherapy in Glioblastoma: Peaks and Pits
New studies in glioblastoma highlight how PD-1 inhibitors could simultaneously prompt an immune response and steer the selection of tumor clones that evade immune recognition.
Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
“People have shown that the variant-identification quality of WGS is superior to WES,” said Dr Gerstein.
Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.
Reducing the Reliance on Opioids for Cancer Pain: Is the Switch to Cannabis a Viable Option?
Articles discussing the use of cannabis as a substitute for opioids highlight the limitations of the existing scientific evidence in the field.
Cancer Death Rates Continue to Decline, but Socioeconomic Gaps Widen
The continuous decline in cancer deaths over the past 25 years was attributed to improvements in screening, treatment.
Should Widespread Early Detection Cancer Screening End?
Experts examined the role of population-based early detection cancer screening.
Next post in General Oncology
